United Therapeutics Corp. (NASDAQ:UTHR) COO Roger Jeffs unloaded 10,000 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $77.86, for a total transaction of $778,600.00. Following the completion of the sale, the chief operating officer now directly owns 19,760 shares of the company’s stock, valued at approximately $1,538,514. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on UTHR. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock.
One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $64.20.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 77.40 on Tuesday. United Therapeutics Corp. has a 52-week low of $44.51 and a 52-week high of $79.95. The stock has a 50-day moving average of $74.34 and a 200-day moving average of $67.62. The company has a market cap of $3.864 billion and a P/E ratio of 13.35.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 24.4% on a year-over-year basis. On average, analysts predict that United Therapeutics Corp. will post $5.99 earnings per share for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.